EO Care Appoints William Fleming and Kristi Savacool to Board of Directors, Reinforcing Its Leadership in Clinically Guided Cannabinoid Symptom Management
Former Humana and Aon Hewitt executives join as directors and investors amid accelerating clinical validation, reimbursement expansion, and national growth.
Boston, MA – March 11, 2026 –
EO Care, Inc., a leading provider of clinically guided cannabinoid-based symptom management, today announced the appointment of William Fleming, PharmD, and Kristi Savacool to its Board of Directors. Both join as directors and investors, further strengthening the company’s governance, strategic depth, and national influence as cannabinoid care advances into mainstream healthcare delivery.
The appointments reflect EO Care’s leadership at a defining moment for the industry—marked by accelerating clinical validation, expanding reimbursement pathways, and growing demand from providers and health plans seeking accountable alternatives for complex symptom management.
With the addition of Dr. Fleming and Ms. Savacool, EO Care’s Board of Directors and advisory leadership now include former U.S. Surgeon General Dr. Regina Benjamin and Dr. Jacob Strand, Enterprise Chair of the Center for Palliative Medicine at Mayo Clinic—forming a formidable group of nationally recognized healthcare executives and clinicians. Collectively, this leadership represents rare depth across federal health policy, value-based care, complex clinical delivery, and enterprise healthcare transformation, underscoring EO Care’s standing as a category-defining leader in clinically guided cannabinoid-based symptom management.
“EO Care has clearly established itself as a clinical and operational leader in cannabinoid-based symptom management,” said Sean Collins, CEO and Co-Founder of EO Care. “As the category matures, healthcare stakeholders are looking for rigor, accountability, measurable outcomes, and scalable delivery models. William and Kristi bring the enterprise experience and strategic insight to help us lead this next phase of integration across payer, provider, and government ecosystems.”
Industry-Leading Governance and Healthcare Expertise
Dr. Fleming brings more than three decades of senior leadership at Humana, including serving as President of Healthcare Services, where he led clinical and pharmacy operations serving 12.5 million members across integrated care platforms. His expertise in value-based care, pharmacy integration, and population health aligns directly with EO Care’s evidence-driven model and its engagement with Medicare and commercial reimbursement frameworks.
Ms. Savacool previously served as CEO of Aon Hewitt, leading a global organization serving more than 20,000 clients and approximately 30 million plan participants. She also served as CEO of Private Health Management, focused on complex and oncology care navigation. Her experience scaling enterprise healthcare platforms and aligning employer, payer, and clinical stakeholders strengthens EO Care’s position as a trusted partner for responsible cannabinoid integration.
Ms. Savacool currently serves on the Boards of Directors of TrueBlue and RxBenefits and is a member of HealthQuest Capital’s Industry Advisory Board. She most recently served on the boards of Ascension Health System and Private Health Management.
Demonstrated Clinical Impact and Market Momentum
Leading the Next Phase of Integration
With policy frameworks evolving and clinical evidence expanding, EO Care continues to engage healthcare trade organizations, provider associations, employer coalitions, and policymakers to advance thoughtful, evidence-based integration of cannabinoid care within established delivery systems.
“Emerging treatment categories require disciplined governance and measurable performance standards,” said Dr. Fleming. “EO Care has built the infrastructure and clinical framework necessary to lead responsibly at scale.”
“The future of symptom management demands innovation anchored in accountability,” said Ms. Savacool. “EO Care is well positioned to help define and advance this category as it becomes more fully integrated into mainstream healthcare.”
About EO Care, Inc.
EO Care is a leader in cannabinoid-based symptom management, delivering personalized, clinically responsible care through its proprietary digital health platform and federally legal hemp-derived cannabinoid therapeutics. The company partners with providers, payers, employers, and health systems to improve patient-reported outcomes and reduce total cost of care.
For more information, visit https://eo.care.
Contact
EO Care Media Relations press@eo.care
The Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.
As the leader in cannabinoid based symptom management for older adults, we applaud the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for federally legal, hemp-derived cannabinoid-based products. At EO, we are uniquely positioned to meet the need of this new, covered cannabinoid care market.
At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2026 All rights reserved. Patents pending. EO Care, Inc.
